Aanhoudende koorts zonder focus met lymfadenopathieën: infectie, inflammatie of maligniteit?

2021 ◽  
Author(s):  
S. DESMEDT ◽  
V. DESMEDT ◽  
T. BILLIET ◽  
C. GEORGE ◽  
W. MEERSSEMAN ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Bone Marrow ◽  
Lymph Nodes ◽  
Unknown Origin ◽  
Lymph Node Biopsy ◽  
Positron Emission ◽  
Pet Ct ◽  
Auto Inflammatory Disease ◽  
Diagnostic Work ◽  
Cardinal Symptoms

Persistent fever without focus but with lymphadenopathy: infection, inflammation or malignancy? Adult-onset Still’s disease (AOSD) is a rare auto-inflammatory disease in which four cardinal signs have been described: rash, spiking fever, arthritis or arthralgia and hyperleucocytosis with neutrophilia. Nevertheless, diagnosis can be challenging as infectious, other inflammatory or neoplastic diseases need to be ruled out. It affects typically young adults (from 16 to 35 years). The disease can be controlled with non-steroidal anti-inflammatory agents and glucocorticoids. To date, treatments as Il-6, IL-1 or anti-TNFα can be used in glucocorticoid-dependent or refractory patients. We present a case of a 22-year old woman with all four cardinal symptoms in which all cultures and infectious serology resulted negative. Also, auto-immune markers were negative. Because of diffuse bilateral supra- and infradiaphragmatic enlarged lymph nodes up to 1.6 cm in size on computed tomography (CT), additional positron emission tomography-computed tomography imaging (PET-CT-scan) was performed. Besides the multiple enlarged lymph nodes, increased tracer capture was shown in the spleen and bone marrow. All of this was suspicious for high-grade lymphoma. Eventually, an additional bone marrow biopsy with aspiration and lymph node biopsy could rule out a lymphoproliferative process and the diagnosis of AOSD could be made. This case report highlights the importance of a profound diagnostic work-up in fever of unknown origin.

Positron emission tomography/computed tomography to improve staging and restaging in Merkel cell carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8552-8552
Author(s):  
Elena B. Hawryluk ◽  
Kevin N. O'Regan ◽  
Niall Sheehy ◽  
Ye Guo ◽  
Andrew Dorosario ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Lymph Nodes ◽  
Emission Tomography ◽  
Merkel Cell ◽  
Regional Lymph Nodes ◽  
Positron Emission ◽  
Pet Ct ◽  
Bone Marrow Metastases

8552 Background: Merkel cell carcinoma (MCC) is a rare (~1,500 cases per year) and highly aggressive (33% mortality) cutaneous neuroendocrine carcinoma that occurs in older white patients on the UV-exposed skin of the head, neck, and extremities. As a patient’s stage at presentation is a strong predictor of survival, and there is a high propensity for locoregional recurrence and distant progression, imaging remains crucial for initial and subsequent management. There is, however, no consensus on the timing or method of imaging for MCC. Methods: We retrospectively reviewed 270 2-fluoro-[18F]-deoxy-2-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) scans performed in 97 patients at the Dana-Farber/Brigham and Women’s Cancer Center from August 2003 to December 2010. Results: The mean SUVmax was 6.5 for primary tumors, 6.4 for regional lymph nodes, 7.2 for distant metastases (all sites), 8.0 for bone/bone marrow metastases, and 9.4 for non-regional metastases in those patients with no identified primary. PET/CT imaging performed for initial management tended to upstage patients with more advanced disease (50% of stage IIIB patients). Metastases to bone/bone marrow (12 patients, 38%) was the 2nd most common site of distant spread after non-regional lymph nodes (19 patients, 59%), followed by skin (8 patients, 25%), liver (6 patients, 19%), lung/pleura (5 patients, 16%), adrenal (3 patients, 9%), muscle (3 patients, 9%), pancreas (2 patients, 6%), and peritoneum (1 patient, 3%). In 10 of 12 patients, PET identified bone/bone marrow metastases that were not seen on CT imaging, which resulted in either upstaging or initiation of more targeted palliative therapy. Conclusions: Added value of PET over CT, such as in the detection of bone/bone marrow metastases, may lead to more accurate staging, and thus prognostication, as well as earlier detection of relapse and initiation of salvage treatment. Its use should be considered in the staging and restaging of MCC.

scholarly journals Mediastinal Staging for Lung Cancer

2014 ◽  
Vol 21 (3) ◽  
pp. 159-161 ◽  
Author(s):  
Jacob Gelberg ◽  
Sean Grondin ◽  
Alain Tremblay
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Lymph Nodes ◽  
Emission Tomography ◽  
Mediastinal Staging ◽  
Positron Emission ◽  
Pet Ct ◽  
Diagnosis Of Cancer ◽  
Rule Out

Staging of the mediastinal and hilar lymph nodes plays a crucial role in identifying the best treatment option for patients with confirmed or suspected lung cancer and, in many cases, can simultaneously confirm a diagnosis of cancer. Noninvasive modalities, such as computed tomography (CT), positron emission tomography (PET) and PET-CT, are an important first step in this assessment. Ultimately, invasive staging is frequently required to confirm or rule out the presence of metastatic disease within the lymph nodes. The present focused review describes and compares noninvasive and invasive modalities for mediastinal staging in lung cancer.

scholarly journals Chylothorax: The Unusual Suspect

2019 ◽  
Vol 05 (02) ◽  
pp. 075-077
Author(s):  
Anusha C. Madhusoodan ◽  
Gajanan S. Gaude
Keyword(s):  
Computed Tomography ◽  
Lymph Node Biopsy ◽  
Emission Tomography ◽  
Supraclavicular Lymph Node ◽  
Node Biopsy ◽  
Positron Emission ◽  
Lymphatic Duct ◽  
Pet Ct ◽  
Hodgkin's Lymphomas

AbstractA chylothorax results when the lymphatic duct becomes disrupted. It is an uncommon and poorly described complication of both Hodgkin’s and non-Hodgkin’s lymphomas of any histological type and grade. A 62-year-old female presented with dyspnea on exertion and dry cough for 15 days. Chest radiograph showed left-sided effusion. Pleural fluid reports were suggestive of chylothorax. Fluid was drained and CT thorax was performed which revealed multiple supra- and infradiaphragmatic lymphadenopathy. Left supraclavicular lymph node biopsy revealed chronic inflammation. Immunohistochemistry of the same sample was reported as non-Hodgkin’s lymphoma of follicular type grade I/III (2008). Positron emission tomography-computed tomography (PET-CT) showed hypermetabolic areas in supra- and infradiaphragmatic lymph nodes and also in multiple bones (with surrounding regions encasement). Patient has received two cycles of chemotherapy with Bendamustine and Rituximab. She is on regular follow-up with the oncologist and doing fine.

scholarly journals Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Molecules ◽  
2019 ◽  
Vol 25 (1) ◽  
pp. 134 ◽  
Author(s):  
Christos Sachpekidis ◽  
Hartmut Goldschmidt ◽  
Antonia Dimitrakopoulou-Strauss
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Disease ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer 18F-fluorodeoxyglucose (18F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET/CT with different radiopharmaceuticals in the clinical practice of MM.

Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma

2012 ◽  
Vol 30 (36) ◽  
pp. 4508-4514 ◽  
Author(s):  
Tarec Christoffer El-Galaly ◽  
Francesco d'Amore ◽  
Karen Juul Mylam ◽  
Peter de Nully Brown ◽  
Martin Bøgsted ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Risk Assessment ◽  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Hodgkin Lymphoma ◽  
Bone Marrow Biopsy ◽  
Emission Tomography ◽  
Newly Diagnosed ◽  
Positron Emission ◽  
Pet Ct

Purpose To investigate whether bone marrow biopsy (BMB) adds useful information to [18F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) staging in patients with Hodgkin lymphoma (HL). Patients and Methods Newly diagnosed patients with HL undergoing a pretherapeutic staging that encompasses both PET/CT and BMB were included in this retrospective study. The pattern of skeletal FDG uptake was categorized as uni-, bi-, or multifocal (≥ three lesions). Clinical stage, risk assessment, and treatment plan were determined with and without the contribution of BMB results according to the Ann Arbor classification and the guidelines from the German Hodgkin Study Group. Results A total of 454 patients with HL were included of whom 82 (18%) had focal skeletal PET/CT lesions and 27 (6%) had positive BMB. No patients with positive BMB were assessed as having stage I to II disease by PET/CT staging. BMB upstaged five patients, assessed as being stage III before BMB; none of the 454 patients would have been allocated to another treatment on the basis of BMB results. Focal skeletal PET/CT lesions identified positive and negative BMBs with a sensitivity and specificity of 85% and 86%, respectively. The positive and negative predictive values of focal skeletal PET/CT lesions for BMB results were 28% and 99%, respectively. Conclusion A consistent finding of this study was the absence of positive BMBs in PET/CT-assessed stage I to II disease. The omission of staging BMB would not have changed the risk assessment or treatment strategy in this cohort of 454 newly diagnosed patients with HL.

The role of positron emission tomography combined with computed tomography in the diagnosis and evaluation of treatment effectiveness of non-small cell lung cancer

2016 ◽  
Vol 21 (3) ◽  
pp. 160-164
Author(s):  
Nadezhda A. Meshcheryakova ◽  
M. B Dolgushin ◽  
M. M Davydov ◽  
K. K Laktionov ◽  
A. A Odzharova ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Lymph Nodes ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Emission Tomography ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Pet Ct

Single photon emission computed tomography (SPECT) with the use of various tumor-tropic radiopharmaceutical preparations (RFP) has shown its effectiveness in the identification of tumor process in the lungs and metastatic lesions of mediastinal lymph nodes. In lung cancer such RFPs as Technetium-99m methoxy isobutyl isonitrile (MIBI) I) and 99mTc-depreotid got the largest traction. Increasingly frequently for the initial assessment of the prevalence ofprimary non-small cell lung cancer (NSCLC) there was used positron emission tomography combined with computed tomography (PET/CT) with 2-[18F]Fluoro-2-deoxy-d-glucose ([18F]FDG). The combined PET/CT image consider metabolic and morphological data, that allows to localize precisely the dissemination of the process and is used for the confirmation of the stage, detection of metabolically active extrathoracic lymph nodes, including those of the standard size (

Imaging a Fever—Redefining the Role of 2-deoxy-2-[18F]Fluoro-D-Glucose–Positron Emission Tomography/Computed Tomography in Fever of Unknown Origin Investigations

2020 ◽  
Author(s):  
William F Wright ◽  
Paul G Auwaerter ◽  
Elizabeth H Dibble ◽  
Steven P Rowe ◽  
Philip A Mackowiak
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fever Of Unknown Origin ◽  
Imaging Technique ◽  
Unknown Origin ◽  
Emission Tomography ◽  
18Fdg Pet ◽  
Positron Emission ◽  
Pet Ct ◽  
Abnormal Uptake

Abstract Growing evidence suggests that 2-deoxy-2-[18F]fluoro-D-glucose (18FDG)–positron emission tomography/computed tomography (PET/CT) is a useful imaging technique for the evaluation of fever of unknown origin (FUO). This imaging technique allows for accurate localization of foci of hypermetabolism based on 18FDG uptake in glycolytically active cells that may represent inflammation, infection, or neoplasia. The presence of abnormal uptake can help direct further investigation that may yield a final diagnosis. A lack of abnormal uptake can be reasonably reassuring that these conditions are not present, thereby avoiding unnecessary additional testing. Insurers have not routinely covered outpatient 18FDG-PET/CT for the indication of FUO in the United States. However, data published since 2007 suggest early use in FUO diagnostic evaluations improves diagnostic efficiency and reduces costs. Clinicians and insurers should consider 18FDG-PET/CT as a useful tool when preliminary studies are unrevealing.

Sign in / Sign up

Export Citation Format

Share Document